Startups

Subsense

Palo Alto, California, United States

Private developer of investigational nanoparticle-based non-surgical NanoBCI technology. Publicly launched February 2025; no longer stealth. CEO Tetiana Aleksandrova. Disclosed seed financing comprises $17M plus a $10M extension, totaling $27M.

Team

Amy PeckHead of Partnerships

Andrew OstarelloChief Strategy Officer

Anthony Di PasquaActing Director, R&D Execution

Artem SokolovCo-founder

David EaglemanAdvisor

Parminder MankooHead of AI

Ray KurzweilAdvisor

Rose MonaghanSenior R&D Director

Sasha IsaenkoHead of Operations

Scott MeekHead of R&D & co-founder

Tetiana AleksandrovaCEO & co-founder

Investments

$10M2025-12-11	0 participations
$17M2025-02-18	Golden Falcon Capital

team@apexlogos.ai2 days ago
RELATED
team@apexlogos.ai2 days ago
BCI research snapshot, reviewed 2026-10-06. Company identity: Subsense. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 1/1 # Subsense Research date / sources accessed: **2026-10-06**. Review document only; no database mutations. ## Entity and pasted-list validation **Real private company, Subsense, Inc.**, official [subsense-bci.com](https://subsense-bci.com/). Current official contact is **2445 Faber Pl, Palo Alto, CA 94303**, rather than assuming the pasted San Francisco headquarters. Founding year not established in the consulted primary pages. The [company announcement](https://www.neurofounders.co/press-releases/subsense-emerges-from-stealth-with-17m-in-seed-funding-for-a-non-surgical-brain-computer-interface) identifies founders Tetiana Aleksandrova and Artem Sokolov, CEO Aleksandrova and $17M seed, February 18, 2025. Current [official roster](https://subsense-bci.com/about-us/) additionally calls Scott Meek a co-founder. These are not mutually exclusive but the founder history requires careful attribution. The pasted CEO is correct. **STEALTH is false/outdated**: the company publicly emerged February 2025 and now publishes its roster and technology. Product is an investigational, nanoparticle-based non-surgical NanoBCI. The [home page](https://subsense-bci.com/) explicitly says products are not FDA authorized/cleared/approved and performance claims have not been evaluated. Non-surgical does not mean proof of safe, effective, consumer-ready brain access. Pasted **USD $27M** is supported by the current company home-page disclosure; preserve its seed nature. ## Existing adex match No Subsense name match in read-only Org search. Suggested new ID `Subsense`, conditional on review. No database changes made. ## Profile images and leadership [Direct official logo](https://subsense-bci.com/wp-content/themes/core/src/images/logo.svg), from [about HTML](https://subsense-bci.com/about-us/). The following portraits come from each named team card's `img src`. Earlier staging site's Gary Lo CFO and Andrew Ostarello Chief of Staff are stale relative to this live roster; CFO is advertised as a vacancy. | Person | Role / timing | Profile / evidence | Direct profile-picture URL | |---|---|---|---| | Tetiana Aleksandrova | CEO & co-founder, current | [Official profile/team](https://subsense-bci.com/about-us/) | [Image](https://subsense-bci.com/wp-content/uploads/2025/06/Tanya4.webp) | | Andrew Ostarello | Chief Strategy Officer, current | [Official profile/team](https://subsense-bci.com/about-us/) | [Image](https://subsense-bci.com/wp-content/uploads/2026/02/image-164.webp) | | Scott Meek | Head of R&D & co-founder, current | [Official profile/team](https://subsense-bci.com/about-us/) | [Image](https://subsense-bci.com/wp-content/uploads/2025/06/Scott-Final.webp) | | Rose Monaghan | Senior R&D Director, current | [Official profile/team](https://subsense-bci.com/about-us/) | [Image](https://subsense-bci.com/wp-content/uploads/2026/02/image-165-1.webp) | | Sasha Isaenko | Head of Operations, current | [Official profile/team](https://subsense-bci.com/about-us/) | [Image](https://subsense-bci.com/wp-content/uploads/2025/06/Sasha-FINAL.webp) | | Amy Peck | Head of Partnerships, current | [Official profile/team](https://subsense-bci.com/about-us/) | [Image](https://subsense-bci.com/wp-content/uploads/2026/05/AmyPeckHeadshot_8x10-copy-e1780366259892.webp) | | Parminder Mankoo | Head of AI, current | [Official profile/team](https://subsense-bci.com/about-us/) | [Image](https://subsense-bci.com/wp-content/uploads/2026/05/Parminder-2-e1780366544685.webp) | | Anthony Di Pasqua | Acting Director, R&D Execution, current | [Official profile/team](https://subsense-bci.com/about-us/) | [Image](https://subsense-bci.com/wp-content/uploads/2025/06/Anthony-final.webp) | Artem Sokolov — co-founder named in [launch announcement](https://www.neurofounders.co/press-releases/subsense-emerges-from-stealth-with-17m-in-seed-funding-for-a-non-surgical-brain-computer-interface); no portrait in current inspected company leadership cards. Current operating role beyond founding/investor relationship not established. Advisors include Ray Kurzweil and David Eagleman; advisory roles must not become executive employment. Their official portraits: [Kurzweil](https://subsense-bci.com/wp-content/uploads/2026/05/Ray-Kurzweil-Joins-Subsense.svg), [Eagleman](https://subsense-bci.com/wp-content/uploads/2026/04/Eagleman.webp), evidence [advisor roster](https://subsense-bci.com/about-us/). ## Sourced investments | Announced | Amount / currency | Round | Lead / investors | Evidence | |---|---|---|---|---| | 2025-02-18 | USD 17M | Seed | Golden Falcon Capital, led by co-founder Artem Sokolov | [Company-issued launch release](https://www.neurofounders.co/press-releases/subsense-emerges-from-stealth-with-17m-in-seed-funding-for-a-non-surgical-brain-computer-interface) | | 2025-12-11 | USD 10M additional; cumulative seed USD 27M | Seed extension | Additional investors not named in accessible official home disclosure; do not guess | [Official home-page cumulative + additional seed disclosure](https://subsense-bci.com/); company links original interview, [Axios source](https://www.axios.com/pro/biotech-deals/2025/12/11/subsense-raises-10m-for-neurotech) | The announced/desired USD100M Series A mentioned in press interviews is a fundraising target, not a closed investment. No verified later closing, IPO, acquisition or debt schedule in the consulted company sources. No corporate grants confirmed. ## Review / import decision Candidate for new private-company import with early-stage investigational status. Import verified seed history, actual public team and official profile URLs. Hold founding year, complete legal incorporation particulars and extension investor identities until supported; avoid importing marketing potential-patient counts as outcomes.